Chai Discovery

Research on the record

• 2025-11-19Chai Discovery reports Chai-2 designing full-length antibodies that pass developability screens, and binders to six GPCRsLevel 4 · Tested in the physical world
• 2025-07-06Chai Discovery's Chai-2 preprint reports a 16% hit rate designing antibodies from scratch, across 52 targetsLevel 4 · Tested in the physical world
• 2024-09-09Chai Discovery releases Chai-1, a structure-prediction model with open weights that companies may useLevel 2 · Computed

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-10-09GSK takes Chai Discovery's design models across its pipeline after its own lab found binders to every target it testedPartnerships
• 2026-07-14Chai Discovery raises $400M at a $3.8B valuation, led by Index VenturesCapital

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-07-14Series C · $400MconfirmedLed by Index Ventures · With Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital · Existing investors Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, YosemiteStated use: compute, data and research behind its models; product development; bringing its models to more scientists
• 2025-12-15Series B · $130MconfirmedLed by Oak HC/FT, General Catalyst · With Menlo Ventures, OpenAI, Thrive Capital, Dimension, Glade Brook, Emerson Collective, Lachy Groom, Yosemite, Neo, SV AngelStated use: develop its 'computer-aided design suite' for molecules
• 2025-08-06Series A · $70MconfirmedLed by Menlo Ventures (incl. Anthology Fund with Anthropic) · With Yosemite, DST Global Partners, Avenir, DCVC, SV Angel, Byers Capital, Anthropic · Existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, Fred EhrsamStated use: develop the platform, take on new targets, onboard select partners
• 2024-09-09Seed · nearly $30 millionconfirmedLed by Thrive Capital · With OpenAI, Dimension Capital, Nitesh BantaStated use: develop foundation models for molecular structure

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
• 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.
• 2026-02-26Generate:BiomedicinesIPO · $400MA Flagship company using generative AI to design protein drugs such as antibodies, peptides and enzymes, and developing them itself.

All 15 in this field →